The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience - PubMed
5 hours ago
- #chemotherapy
- #refractory
- #neuroblastoma
- BIT (Bevacizumab/Irinotecan/Temozolomide) is recommended for relapsed/refractory neuroblastoma in the UK since 2021.
- A retrospective study included 66 patients under 25 years from 15 UK centers treated with BIT.
- Overall objective response rate was 40.6%, higher in refractory (56%) vs. relapsed (31%) disease.
- Progression-free survival (PFS) and overall survival (OS) were significantly longer in refractory patients.
- Common Grade 3-4 toxicities included anemia (32%), neutropenic fever (23%), and diarrhea (13.6%).
- BIT showed promising efficacy and tolerability in real-world data, supporting BEACON trial findings.
- Further randomized studies are needed to optimize treatment for relapsed and refractory neuroblastoma.